Chris Pickford

875 total citations
15 papers, 649 citations indexed

About

Chris Pickford is a scholar working on Virology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Chris Pickford has authored 15 papers receiving a total of 649 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Virology, 6 papers in Infectious Diseases and 5 papers in Molecular Biology. Recurrent topics in Chris Pickford's work include HIV Research and Treatment (7 papers), HIV/AIDS drug development and treatment (6 papers) and Hepatitis C virus research (4 papers). Chris Pickford is often cited by papers focused on HIV Research and Treatment (7 papers), HIV/AIDS drug development and treatment (6 papers) and Hepatitis C virus research (4 papers). Chris Pickford collaborates with scholars based in United Kingdom, United States and Belgium. Chris Pickford's co-authors include Stephen M. Shaw, Mike Westby, Manos Perros, Scott L. Butler, Wade Blair, Amy K. Patick, Hua Wu, Joan Cao, Jason Isaacson and Andrew D. Scott and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer Research.

In The Last Decade

Chris Pickford

13 papers receiving 640 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chris Pickford United Kingdom 10 408 373 244 137 124 15 649
Robert S. Wehbie United States 11 399 1.0× 428 1.1× 163 0.7× 173 1.3× 31 0.3× 17 707
Julie Q. Hang United States 16 165 0.4× 340 0.9× 257 1.1× 228 1.7× 238 1.9× 20 718
Jason Isaacson United States 6 317 0.8× 269 0.7× 108 0.4× 58 0.4× 36 0.3× 6 376
Sarah Mosier United States 9 413 1.0× 402 1.1× 148 0.6× 155 1.1× 192 1.5× 11 671
Malcolm Macartney United Kingdom 9 663 1.6× 523 1.4× 284 1.2× 213 1.6× 106 0.9× 19 1.1k
Veerle Van Eygen Belgium 18 671 1.6× 702 1.9× 230 0.9× 199 1.5× 115 0.9× 36 936
Belete A. Desimmie United States 13 753 1.8× 701 1.9× 575 2.4× 177 1.3× 25 0.2× 24 1.1k
Mark F. Kavlick United States 20 1.1k 2.7× 1.2k 3.1× 377 1.5× 215 1.6× 68 0.5× 30 1.6k

Countries citing papers authored by Chris Pickford

Since Specialization
Citations

This map shows the geographic impact of Chris Pickford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Pickford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Pickford more than expected).

Fields of papers citing papers by Chris Pickford

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Pickford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Pickford. The network helps show where Chris Pickford may publish in the future.

Co-authorship network of co-authors of Chris Pickford

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Pickford. A scholar is included among the top collaborators of Chris Pickford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Pickford. Chris Pickford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Hairsine, Brigid, Hassan M. Rostam, Sascha A. Kristian, et al.. (2025). Harnessing endogenous anti-glycan antibodies using a novel, bifunctional immunotherapy to treat gram-negative bacterial infections. The Journal of Immunology. 214(7). 1617–1629.
2.
Martin, Bénédicte, Elizabeth Horsley, Laurie Baxter, et al.. (2025). Abstract 6736: Preclinical development of ADCT-241, a novel exatecan-based antibody-drug conjugate targeting PSMA for the treatment of prostate cancer. Cancer Research. 85(8_Supplement_1). 6736–6736.
3.
Cucchi, Danilo, et al.. (2025). Abstract 1580: HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers. Cancer Research. 85(8_Supplement_1). 1580–1580. 1 indexed citations
4.
Shaw, Stephen M., Kim Wigglesworth, Oliver Schulz, et al.. (2019). AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models. Cancer Cell International. 19(1). 346–346. 12 indexed citations
5.
Kristian, Sascha A., Stephen M. Shaw, Kim Wigglesworth, et al.. (2016). AGI-134, a fully synthetic α-Gal-based cancer immunotherapy: Synergy with an anti-PD-1 antibody and pre-clinical pharmacokinetic and toxicity profiles.. Journal of Clinical Oncology. 34(15_suppl). 3083–3083. 2 indexed citations
6.
Pryde, David C., Rob Webster, Scott L. Butler, et al.. (2013). Discovery of an HIV integrase inhibitor with an excellent resistance profile. MedChemComm. 4(4). 709–709. 10 indexed citations
7.
Christ, Frauke, Stephen M. Shaw, Jonas Demeulemeester, et al.. (2012). Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization. Antimicrobial Agents and Chemotherapy. 56(8). 4365–4374. 135 indexed citations
8.
Pickford, Chris, Frauke Christ, Stephen M. Shaw, et al.. (2011). Pre-clinical evaluation of HIV replication inhibitors that target the HIV-integrase-LEDGF/p75 interaction. Journal of the International AIDS Society. 15. 26–27. 3 indexed citations
9.
Shaw, Stephen M., et al.. (2011). Colony-forming assays reveal enhanced suppression of hepatitis C virus replication using combinations of direct-acting antivirals. Journal of Virological Methods. 174(1-2). 153–157. 11 indexed citations
10.
Targett‐Adams, Paul, Amy E. Palmer, Stephen M. Shaw, et al.. (2011). Small Molecules Targeting Hepatitis C Virus-Encoded NS5A Cause Subcellular Redistribution of Their Target: Insights into Compound Modes of Action. Journal of Virology. 85(13). 6353–6368. 91 indexed citations
11.
Laxton, Carl, Kevin Brady, Sterghios Moschos, et al.. (2011). Selection, Optimization, and Pharmacokinetic Properties of a Novel, Potent Antiviral Locked Nucleic Acid-Based Antisense Oligomer Targeting Hepatitis C Virus Internal Ribosome Entry Site. Antimicrobial Agents and Chemotherapy. 55(7). 3105–3114. 40 indexed citations
12.
Blair, Wade, Chris Pickford, S.L. Irving, et al.. (2010). HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention. PLoS Pathogens. 6(12). e1001220–e1001220. 241 indexed citations
13.
Murray, Edward J., Daniel P. Leaman, Chris Pickford, et al.. (2010). A Low-Molecular-Weight Entry Inhibitor of both CCR5- and CXCR4-Tropic Strains of Human Immunodeficiency Virus Type 1 Targets a Novel Site on gp41. Journal of Virology. 84(14). 7288–7299. 24 indexed citations
14.
Blair, Wade, Joan Cao, Juin Fok‐Seang, et al.. (2009). New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation. Antimicrobial Agents and Chemotherapy. 53(12). 5080–5087. 50 indexed citations
15.
Parrish, Randall R., M.F. Thirlwall, Chris Pickford, et al.. (2006). DETERMINATION OF 238U/235U, 236U/238U AND URANIUM CONCENTRATION IN URINE USING SF-ICP-MS AND MC-ICP-MS: AN INTERLABORATORY COMPARISON. Health Physics. 90(2). 127–138. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026